Hill Holliday nets Diovan

Share this article:
Novartis shifted the DTC account for Diovan from Deutsch to Hill, Holliday, Connors, Cosmopoulos.

Both Hill Holliday and Deutsch are Interpublic companies. There was no pitch for the business, which will be handled out of Boston-based Hill Holliday's New York office. It's a coup for Hill Holliday, which has been seeking an in on the pharmaceutical sector. Hill Holliday healthcare accounts include CVS and Cleveland Clinic.  

Deutsch continues to handle the rest of Novartis' cardiology franchise, including Lotrel and BP Success Zone. The agency will also handle consumer advertising for two forthcoming Novartis cardiovascular products, due to launch in 2007 and 2008.

The move, first reported by Advertising Age, comes ahead of Novartis' first branded consumer work for Diovan in several years. It was previously incorporated into part of BP Success Zone.
Diovan boasted US sales of $1.3 billion for the nine months to September—up 19% year on year—with total worldwide sales of $3 billion for the period. The company presented data last month to the American Heart Association showing that the drug, given at high doses, could help diabetics. Results from a 391-patient trial showed that the drug reduced protein levels in the urine of patients.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...